Saptak Chem Narrows Quarterly Loss Amid Persistent Revenue Challenge
The chemical trader's quarterly loss improved sequentially, but the company reported zero revenue for the fifth consecutive quarter.
Saptak Chem & Business reported a smaller loss in Q1 FY26 compared to the previous quarter. However, the company's revenue remained at zero, a trend now extending over a full year.
Saptak Chem & Business posted a smaller loss for the quarter ended June 2025, showing some improvement from the prior three-month period. The company's core challenge, however, remains unchanged: it has reported zero revenue for five consecutive quarters, indicating its trading operations have yet to generate sales.
The latest quarterly loss stood at ₹0.06 crore, a 25% improvement from the ₹0.08 crore loss in the March 2025 quarter. Over the past twelve months (TTM), the total loss amounts to ₹0.14 crore. The complete absence of revenue over this extended period overshadows the marginal profit improvement.
A look at the recent quarters shows the persistent pattern of zero sales.
Revenue (₹ Cr)
Profit (₹ Cr)
| Metric | CurrentQ1 FY26 | PreviousQ4 FY25 | Same quarter LYQ1 FY25 |
|---|---|---|---|
| Period Ended | June 2025 | March 2025 | June 2024 |
| Revenue (₹ Cr) | 0.00 | 0.00 | 0.00 |
| Profit (₹ Cr) | -0.06 | -0.08 | 0.00 |
Key Points
- The company's annual loss for FY25 was ₹0.09 crore.
- Despite the lack of revenue, Saptak Chem maintains a strong current ratio of 5.75, indicating good short-term liquidity.
- Its trailing twelve-month earnings per share (EPS) is negative at -0.13.
The immediate priority for Saptak Chem is to reignite its trading business and translate its stated strategy of market expansion into actual revenue.
Live Chart
· SAPTAK CHEM
(BSE)
ISIN: INE467X01015
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.